Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLIVA/Mayne filgrastim versus Neupogen in breast cancer chemotherapy-induced neutropenia
2007-000394-36Phase 3Completed
- Sponsor
- Hospira, Inc.
- Start
- May 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgrastim in neutropenia and febrile neutropenia (FN) (2 arms), sponsored by Hospira, Inc. Primary endpoints: Duration of severe neutropenia and Febrile neutropenia incidence. Started May 2007; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on 2007-000394-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000394-36.